ANI Pharmaceuticals, Inc.ANIPNASDAQ
Loading
Operating Income Growth AcceleratingAccelerating
Percentile Rank79
3Y CAGR-6.6%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-6.6%/yr
Quarterly compound
Percentile
P79
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 111.00% |
| Q3 2025 | 64.35% |
| Q2 2025 | -46.96% |
| Q1 2025 | 698.31% |
| Q4 2024 | 78.66% |
| Q3 2024 | -496.96% |
| Q2 2024 | -74.55% |
| Q1 2024 | 201.99% |
| Q4 2023 | -62.53% |
| Q3 2023 | 44.72% |
| Q2 2023 | 25.34% |
| Q1 2023 | 443.68% |
| Q4 2022 | 136.44% |
| Q3 2022 | 61.32% |
| Q2 2022 | 32.73% |
| Q1 2022 | 19.09% |
| Q4 2021 | -566.00% |
| Q3 2021 | 77.10% |
| Q2 2021 | -610.77% |
| Q1 2021 | 819.94% |
| Q4 2020 | -88.19% |
| Q3 2020 | 124.78% |
| Q2 2020 | -44.19% |
| Q1 2020 | -67.89% |
| Q4 2019 | -163.74% |
| Q3 2019 | -21.14% |
| Q2 2019 | 111.09% |
| Q1 2019 | -61.54% |
| Q4 2018 | 13.16% |
| Q3 2018 | 39.25% |
| Q2 2018 | 11.11% |
| Q1 2018 | -11.41% |
| Q4 2017 | -20.92% |
| Q3 2017 | 33.41% |
| Q2 2017 | 51.22% |
| Q1 2017 | 256.32% |
| Q4 2016 | -83.61% |
| Q3 2016 | 52.50% |
| Q2 2016 | -8.33% |
| Q1 2016 | -9.60% |